tiprankstipranks
Paradigm Biopharmaceuticals Issues New Shares Amid Drug Development Focus
Company Announcements

Paradigm Biopharmaceuticals Issues New Shares Amid Drug Development Focus

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.

Pick the best stocks and maximize your portfolio:

Paradigm Biopharmaceuticals Ltd. has issued 40 million fully paid ordinary shares without disclosure under the Corporations Act, affirming compliance with all relevant regulations. The Melbourne-based company is focused on advancing its late-stage drug developments, particularly its injectable treatment for diseases like osteoarthritis and mucopolysaccharidosis.

For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskParadigm Biopharmaceuticals Issues New Performance Rights
TipRanks Australian Auto-Generated NewsdeskParadigm Biopharma Highlights Investment Risks and Cautions
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App